US FDA's Sunscreen Progress Gets Dim Review From Congressional Appropriators

House and Senate appropriators' take note that US FDA has not approved an additional OTC sunscreen ingredient since the 2014 passage of the Sunscreen Innovation Act.

Capitol House

In separate reports on FDA's budget, House and Senate funding committees both say they are "significantly concerned" about FDA's progress to permit marketing of new sunscreen ingredients to be made available.

The Senate report points out that FDA has not approved an additional OTC sunscreen ingredient since implementation of the 2014 Sunscreen Innovation Act

The House and Senate passed separate bills setting FDA's fiscal 2019 direct appropriation from the US Treasury as well as user fee amounts. The House approved its bill in mid-July and the Senate approved its version of the bill on Aug. 1. Each bill is discussed in a report by the respective chambers' Appropriations Committee

More from Legislation

More from Policy & Regulation